NARE ARSHAKYAN: Open Payments
NPI 1609400605 · GLENDALE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$704 in 29 payments from 12 companies in 2025. Trend: 2023 $1,365 · 2024 $1,474 · 2025 $704
Food & beverage: $704
| Company | Payments | Amount |
|---|---|---|
| Genentech USA, Inc. | 4 | $125 |
| Lilly USA, LLC | 4 | $110 |
| ABBVIE INC. | 5 | $96 |
| Lundbeck LLC | 5 | $86 |
| Novartis Pharmaceuticals Corporation | 2 | $69 |
| Neurelis, Inc. | 2 | $47 |
| Alexion Pharmaceuticals, Inc. | 2 | $43 |
| Amgen Inc. | 1 | $34 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $24 |
Products named: Ocrevus Zunovo, VYEPTI, KESIMPTA, KISUNLA, QULIPTA, VALTOCO, ULTOMIRIS, EVENITY.
Industry payments across CA — which companies pay providers there.
